NCT03158324 is a Phase 2 clinical trial of OPB-111077 in NPC, sponsored by National University Hospital, Singapore.

Who is sponsoring NCT03158324?

NCT03158324 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT03158324?

Interventions in NCT03158324: OPB-111077.

What condition does NCT03158324 study?

NCT03158324 studies NPC, Refractory Tumor.

Is NCT03158324 still recruiting?

NCT03158324 is currently status unknown. Last updated 15 June 2017.

Last reviewed 2017-06-15 · How we verify

NCT03158324

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

Status unknown Phase 2 Last updated 15 June 2017

What this trial tests

Phase 2 trial testing OPB-111077 in NPC in 52 participants. Status unknown.

Timeline

22 May 2017

Primary endpoint
22 May 2020

30 November 2020

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	22 May 2017
Primary completion	22 May 2020
Estimated completion	30 November 2020
Sites	1 location across Singapore

Drugs / interventions tested

OPB-111077 — full drug profile →

Conditions studied

NPC — all drugs for NPC →
Refractory Tumor — all drugs for Refractory Tumor →

Sponsor

National University Hospital, Singapore

Who can join

Adults 21 to 99, any sex, with NPC or Refractory Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at study entry.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma.
Lee C, Cheung ST. · · 2019 · cited 101× · PMID 31731457 · DOI 10.3390/cancers11111646
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.
Li J, Eu JQ, Kong LR, Wang L, et al · · 2020 · cited 99× · PMID 33092283 · DOI 10.3390/molecules25204831
Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors.
Lee M, Hirpara JL, Eu JQ, Sethi G, et al · · 2019 · cited 96× · PMID 30594485 · DOI 10.1016/j.redox.2018.101073
Direct Targeting Options for STAT3 and STAT5 in Cancer.
Orlova A, Wagner C, de Araujo ED, Bajusz D, et al · · 2019 · cited 69× · PMID 31817042 · DOI 10.3390/cancers11121930
The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.
Sebestyén A, Dankó T, Sztankovics D, Moldvai D, et al · · 2021 · cited 35× · PMID 35029792 · DOI 10.1007/s10555-021-10006-2
STAT3: Key targets of growth-promoting receptor positive breast cancer.
Jiang RY, Zhu JY, Zhang HP, Yu Y, et al · · 2024 · cited 17× · PMID 39468521 · DOI 10.1186/s12935-024-03541-9
Biophysical Techniques for Target Validation and Drug Discovery in Transcription-Targeted Therapy.
Moustaqil M, Gambin Y, Sierecki E. · · 2020 · cited 8× · PMID 32225120 · DOI 10.3390/ijms21072301

Verify or expand the search:

Other trials of OPB-111077

Trials testing the same drug.

NCT04049825 — A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL · Phase 1 · completed
NCT03197714 — Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia · Phase 1 · completed
NCT02250170 — Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor · Phase 1 · completed
NCT01942083 — A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerabilit · Phase 1 · terminated

Other recruiting trials for NPC

Currently open trials in the same condition.

NCT03734809 — NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer · Phase 2 · active not recruiting
NCT03919552 — Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma · Phase 3 · recruiting

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03158324 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 15 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03158324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing